Home >  News Centre > Bextra (valdecoxib) suspended | Search

Bextra (valdecoxib) suspended
(7 April 2005)

UPDATED: Pharmacists will be reimbursed for patient returns of Bextra (23 April)

Following discussions with the European Medicines Agency, Pfizer has agreed to the suspension of the sale and marketing of Bextra (valdecoxib) throughout Europe as an interim measure pending finalisation of the assessment of COX-2 inhibitors.

Until the completion of a review of COX-2 inhibitors, prescribers are advised to monitor carefully patients being treated with Bextra and not to initiate treatment of new patients. Patients receiving Bextra should speak to their doctor regarding their current treatment.

The Medicines and Healthcare products Regulatory Agency has said that patients should see their doctor at the next convenient appointment to arrange alternative pain relieving treatment.


MHRA
   Letter to healthcare professionals PDF (20K)
   Questions and answers PDF (15K)